241 related articles for article (PubMed ID: 30157717)
1. Relationship between serum vascular cell adhesion molecule-1 and endothelin-1 levels with organ involvement and disease activity in systemic lupus erythematosus patients.
Hajialilo M; Tayari P; Ghorbanihaghjo A; Khabbazi A; Malek Mahdavi A; Rashtchizadeh N
Lupus; 2018 Oct; 27(12):1918-1925. PubMed ID: 30157717
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.
Kuryliszyn-Moskal A; Klimiuk PA; Ciolkiewicz M; Sierakowski S
J Rheumatol; 2008 Jul; 35(7):1307-13. PubMed ID: 18484695
[TBL] [Abstract][Full Text] [Related]
3. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.
Kluz J; Kopeć W; Jakobsche-Policht U; Adamiec R
Int Angiol; 2009 Jun; 28(3):192-201. PubMed ID: 19506538
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
[TBL] [Abstract][Full Text] [Related]
5. Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus.
Cieślik P; Hrycek A
Autoimmunity; 2015 Jun; 48(4):242-50. PubMed ID: 25401491
[TBL] [Abstract][Full Text] [Related]
6. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis.
Kaplanski G; Cacoub P; Farnarier C; Marin V; Grégoire R; Gatel A; Durand JM; Harlé JR; Bongrand P; Piette JC
Arthritis Rheum; 2000 Jan; 43(1):55-64. PubMed ID: 10643700
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schönlein purpura and pediatric systemic lupus erythematosus.
Gattorno M; Vignola S; Barbano G; Sormani MP; Sabatini F; Buoncompagni A; Picco P; Pistoia V
J Rheumatol; 2000 Sep; 27(9):2251-5. PubMed ID: 10990243
[TBL] [Abstract][Full Text] [Related]
8. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
Wais T; Fierz W; Stoll T; Villiger PM
J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
[TBL] [Abstract][Full Text] [Related]
9. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus.
Svenungsson E; Cederholm A; Jensen-Urstad K; Fei GZ; de Faire U; Frostegård J
Scand J Rheumatol; 2008; 37(5):352-9. PubMed ID: 18666029
[TBL] [Abstract][Full Text] [Related]
10. Soluble vascular cell adhesion molecule-1 indicates SLE disease activity and specific organ involvement.
Pizarro S; Monárrez Espino J; Ruiz A; Jara LJ; Nava A; Riebeling-Navarro C
Rev Alerg Mex; 2007; 54(6):189-95. PubMed ID: 18693542
[TBL] [Abstract][Full Text] [Related]
11. Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events.
Demir S; Erten G; Artım-Esen B; Şahinkaya Y; Pehlivan Ö; Alpay-Kanıtez N; Deniz G; Inanç M
Lupus; 2018 Aug; 27(9):1509-1516. PubMed ID: 29954279
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus.
Ho CY; Wong CK; Li EK; Tam LS; Lam CW
Rheumatology (Oxford); 2003 Jan; 42(1):117-22. PubMed ID: 12509624
[TBL] [Abstract][Full Text] [Related]
14. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
Martin-Rodriguez S; Reverter JC; Tàssies D; Espinosa G; Heras M; Pino M; Escolar G; Diaz-Ricart M
Lupus; 2015 Oct; 24(11):1143-9. PubMed ID: 25824235
[TBL] [Abstract][Full Text] [Related]
15. Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1.
Lewis MJ; Vyse S; Shields AM; Zou L; Khamashta M; Gordon PA; Pitzalis C; Vyse TJ; D'Cruz DP
Arthritis Res Ther; 2016 Jan; 18():5. PubMed ID: 26746423
[TBL] [Abstract][Full Text] [Related]
16. Elevated soluble intercellular adhesion molecule-1 levels in patients with systemic lupus erythematosus: relation to insulin resistance.
Tso TK; Huang WN
J Rheumatol; 2007 Apr; 34(4):726-30. PubMed ID: 17309130
[TBL] [Abstract][Full Text] [Related]
17. Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity.
Boehme MW; Raeth U; Galle PR; Stremmel W; Scherbaum WA
Clin Exp Immunol; 2000 Jan; 119(1):189-95. PubMed ID: 10606982
[TBL] [Abstract][Full Text] [Related]
18. Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus.
Robak E; Kierstan M; Cebula B; Krawczynska A; Sysa-Jedrzejowska A; Wierzbowska A; Smolewski P; Robak T
Lupus; 2009 Apr; 18(4):332-41. PubMed ID: 19276301
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
[TBL] [Abstract][Full Text] [Related]
20. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.
Kuryliszyn-Moskal A; Klimiuk PA; Sierakowski S
Clin Rheumatol; 2005 Apr; 24(2):111-6. PubMed ID: 15349798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
